Introduction Commercial airplanes fly with an equivalent cabin FiO 2 of 0.15 leading to reduced oxygen saturation (SpO 2 ) in passengers. Although guidelines exist, the evidence-base for recommending supplemental O 2 when flying in children with complex congenital heart disease (CHD) is practically nonexistent. We conducted hypoxic challenge tests (HCT) to determine which children need a pre-flight assessment. Methods Children<16 years with complex CHD were recruited; exclusions were SpO 2 <75%; pulmonary hypertension; oxygen requirement; or concomitant respiratory disease. Children had a standard HCT in a sealed body plethysmograph with FiO 2 of 0.15. We measured SpO 2 , pulse rate, transcutaneous CO 2 (PtcCO 2 ), corrected QT interval (QTc), and total Hb by co-oximetry (SpHb). Supplemental O 2 was given (which meant a 'failed' test) if (1) children with baseline SpO 2 95%-100% desaturated to 85%, (2) or baseline SpO 2 85%-94% desaturated to 15% of their baseline; (3) or baseline SpO 2 75%-84% desaturated to 70%. Results There were 68 children, mean age 3.3 years (range 10 weeks to 14.5 years); 53% were boys. Grouping by normal (95%) vs abnormal baseline SpO 2 (75%-94%), both groups had a significant fall in SpO 2 (p<0.0001). 3/38 (8%) children failed with normal baseline SpO 2 vs 5/32 (16%) with abnormal baseline (non-significant difference). In terms of cardiac status, both groups had a significant fall in SpO 2 (p<0.0001); however in those with no residual for potential R-L shunt 0/ 27 failed vs those with residual potential R-L shunt or who had not undergone repair or who had palliative surgery in whom 8/41 (20%) failed (p<0.02). PtcCO 2 did not change significantly (i.e., no-one hyperventilated to compensate for hypoxia); pulse rate and QTc were not different between groups, and unaffected by the hypoxic state. Conclusions This is the first evidence to help inform which children with CHD need a pre-flight HCT. We suggest all children with residual potential R-L shunt or who have not undergone repair or who have only had palliative surgery should be tested (as 20% are expected to need supplemental O 2 ), whereas those with no potential for R-L shunt need not be. Baseline SpO 2 does not help predict who will need supplemental O 2 when flying.
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